The present invention features legume products having trypsin inhibitory activity and reduced microbial content, methods of decontaminating such legume products, compositions containing such legume products, and the topical application of such legume products or compositions to skin, nails, and hair.

Patent
   7192615
Priority
Feb 28 2001
Filed
Feb 28 2001
Issued
Mar 20 2007
Expiry
Feb 28 2021

TERM.DISCL.
Assg.orig
Entity
Large
10
399
all paid
1. A composition for topical application comprising:
(a) a soy product having been exposed to gamma irradiation and having a trypsin inhibitory activity of at least about 15%; and
(b) a cosmetically-acceptable topical carrier.
2. A composition of claim 1, wherein said soy product has a thiol retention activity of at least about 75%.
3. A composition of claim 1, wherein said soy product is soymilk powder.
4. A composition of claim 1, wherein said soy product is soybean powder.
5. A composition of claim 1, wherein said composition further comprises vitamin A, vitamin B3, vitamin B5, vitamin B12, vitamin C, vitamin K, vitamin E, and derivatives thereof.
6. A composition of claim 1, wherein said composition further comprises 2-dimethylaminoethanol.
7. A composition of claim 1, wherein said composition further comprises salicylic acid, lactic acid, or glycolic acid.
8. A composition of claim 1, wherein said composition further comprises N-acetyl-cysteine.
9. A composition of claim 1, wherein said soy product has a trypsin inhibitory activity of at least about 25%.
10. A composition of claim 9, wherein said soy product has a thiol retention activity of at least about 75%.
11. A composition of claim 9, wherein said soy product is soymilk powder.
12. A composition of claim 9, wherein said soy product is soybean powder.
13. A composition of claim 9, wherein said composition further comprises vitamin A, vitamin B3, vitamin B5, vitamin B12, vitamin C, vitamin K, vitamin E, and derivatives thereof.
14. A composition of claim 9, wherein said composition further comprises 2-dimethylaminoethanol.
15. A composition of claim 9, wherein said composition further comprises salicylic acid, lactic acid, or glycolic acid.
16. A composition of claim 9, wherein said composition further comprises N-acetyl cysteine.

The present invention relates to legume products, topical compositions containing such legume products, and the manufacture and use thereof.

Legume fruits contain high levels of proteins, lipids and carbohydrates. Consequently, legume fruits, such as soybeans, and compositions containing legume fruits are considered a great nutrient for human use. Legume fruits also contain compounds that inhibit protease activity. For example, two protein protease inhibitors were isolated from soybeans in the early 1940's, the Kunitz-type trypsin inhibitor (soybean trypsin inhibitor, STI) and the Bowman-Birk protease inhibitor (BBI). See, e.g., Birk, Int. J. Pept. Protein Res. 25:113-131 (1985) and Kennedy, Am. J. Clin. Neutr. 68:1406S-1412S (1998).

STI inhibits the proteolytic activity of trypsin by the formation of a stable stoichiometric complex. See, e.g., Liu, K., Chemistry and Nutritional value of soybean components. In: Soybeans, chemistry, technology and utilization. pp. 32-35 (Aspen publishers, Inc., Gaithersburg, Md., 1999). STI consists of 181 amino acid residues with two disulfide bridges and is roughly spherically shaped. See, e.g., Song et al., J. Mol. Biol. 275:347-63 (1998).

BBI is an 8 k-Da protein that inhibits the proteases trypsin and chymotrypsin at separate reactive sites. See, e.g., Billings et al., Pro. Natl. Acad. Sci. 89:3120-3124 (1992). STI and BBI are found only in the soybean seed, and not in any other part of the plant. See, e.g., Birk, Int. J. Pept. Protein Res. 25:113-131 (1985).

However, due to its natural origin, high levels of microorganisms are carried on the outside of legume fruits, such as soybeans. Consequently, decontamination processes such as heat, organic/aqueous solvent extraction, land high shear purification may be used to reduce such microorganism concentrations to allow it to be safe for human use, e.g., skin care applications. Applicants, however, have found that these processes, which frequently denature the active compounds in the soy, result in a compromised biological efficacy (e.g., a reduction in protease inhibitory activity) which is important for cosmetic and therapeutic uses to the skin, hair, and nails. Furthermore, such processes also can lead to instability of the soy product as well as to an undesirable odor and color generation. Therefore, there is a commercial need to develop a means to reduce the levels of microbials in soy products without compromising the biological benefits of such products.

The object of the present invention is to provide for a soy product (e.g., that can be used as an ingredient in a skin, hair, or nail care composition) that has reduced microbial content but maintains its protease inhibitory activity. Another object of the invention is to provided for a skin, hair, or nail care composition containing such soy product optionally with other active agents.

The present invention relates to legume products containing reduced microbial content that retains legume's beneficial biological activities, processes for obtaining such legume products, and uses thereof in cosmetic compositions.

The present invention features legume products having trypsin inhibitory activity and reduced microbial content, methods of decontaminating such soy products, and compositions containing such soy products. In one preferred embodiment, the legume product is a soy product.

The present invention also relates to the topical application of legume products or compositions containing such legume products for use in the maintenance of healthy skin, nails, and hair as well as the prevention or the treatment of skin, nails, and hair disorders, including, but not limited to: regulating firmness of the skin, hair, or nails; cleansing the skin, hair or nails; reducing and/or delaying hair or nail growth; straightening and/or lightening of hair; treatment and/or prevention of acne; regulating the tone of skin, hair, or nails; regulating the texture of skin, hair, or nails; regulating wrinkles in skin; treatment of external aggressions in skin, hair, or nails; and beautifying the skin, hair, or nails.

Other features and advantages of the present invention will be apparent from the detailed description of the invention and from the claims

It is believed that one skilled in the art can, based upon the description herein, utilize the present invention to its fullest extent. The following specific embodiments are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. As used herein, all percentages are by weight unless otherwise specified.

As used herein, “trypsin inhibitory activity” means the ability of the legume product at a concentration of 0.1% (w/w) to inhibit the activity of the protease trypsin, as measured by the assay set forth below in Example 2. In one embodiment, the legume products of the present invention have a trypsin inhibitory activity of at least about 15%. In a further embodiment, the legume products of the present invention have a trypsin inhibitory activity of at least about 25%, such as at least about 50%.

As used herein, “thiol retention activity” means the ability of the legume product at a concentration of 1% (w/v) to inhibit smoke-induced loss of thiols, as measured by the assay set forth below in Example 3. In one embodiment, the legume products of the present invention have a thiol retention activity of at least about 75%. In a further embodiment, the legume products of the present invention have an thiol retention activity of at least about 90%, such as at least about 95%.

As used herein, “microbial content” means the amount of bacteria, fungi, and yeast present in the legume product. Examples of means to measure microbial content include, but are not limited to, the AOAC 986.23 Method as set forth in “Official Methods of Analysis of AOAC International,” edited by Patricia Cunniff, Sixteenth Edition, 5th Revision, 1999 (AOAC International) or the USP Method as set forth in “Official Compendia of Standards, USP 24 USP/NF 19”, United States Pharmacopeial Convention, Inc., 2000 (Board of Trustees, United States Pharmacopeial Convention, Inc.).

“Objectionable microbial content” means the amount of bacteria, fungi, and yeast present in the legume product that are harmful to humans, including but not limited to coliform, E. Coli, Salmonella, thermophilic spores, Bacillus, Enterococcus, Staphylococcus, fecal streptococcus, and those listed in “Disinfection, sterilization, and preservation” 4th edition, Seymour S. Block, pp. 887-888 (1991, Lea & Febiger, Malvern, Pa.).

As used herein, “topical application” means directly laying on or spreading on outer skin using, e.g., by use of the hands or an applicator such as a wipe, puff, roller, or spray.

As used herein, “cosmetically-acceptable” means that the product(s) or compound(s) which the term describes are suitable for use in contact with tissues (e.g., the skin) without undue toxicity, incompatibility, instability, irritation, allergic response, and the like.

As used herein, “topical carrier” means one or more compatible solid or liquid filler diluents that are suitable for topical administration to a mammal. Examples of topical carriers include, but are not limited to, water, waxes, oils, emollients, emulsifiers, thickening agents, gelling agents, and mixtures thereof.

As used herein, “regulating the firmness” means the enhancing of the firmness or elasticity, preventing the loss of firmness or elasticity, or preventing or treating sagging, lax and loose skin, hair, or nails. The firmness or elasticity of the skin can be measured by use of a cutometer. See Handbook of Non-Invasive Methods and the Skin, eds. J. Serup & G. Jemec, Chapter 14.3 (1995). The loss of skin elasticity or firmness may be a result of a number of factors, including but not limited to aging, external aggressions, or the result of an application of a cosmetic to the skin, hair, or nails.

As used herein, “regulating the tone” means the lightening and/or darkening of the appearance of the skin, hair, or nails (e.g., lightening pigmented lesions, darkening skin sallowness, and/or evening the color of the skin).

As used herein, “delaying or reducing nail growth” means the delaying or reducing the growth rate of the nail.

As used herein, “delaying or reducing hair growth” means the delaying or reducing the growth rate of the hair and/or width of hair shaft, including, but not limited to, the reducing the visibility or appearance of hair (e.g., hair on the arms, legs, and face).

As used herein, “cleansing” means the removal of dirt and/or oil from the skin, hair, or nail surface.

As used herein, “regulating the texture” means the smoothing of the surface of the skin, hair, or nail to remove either bumps or crevasses on the surface, including, but mot limited to, smoothing or evening the appearance of the skin.

As used herein, “regulating wrinkles in skin” means preventing, retarding, arresting, or reversing the process of wrinkle or fine line formation in skin, including, but not limited to, reducing the visibility or appearance of wrinkles.

As used herein, “treatment of external aggressions” means the reduction or prevention of the damage from external aggressions in skin, hair, or nails. Examples of external aggressions include, but are not limited to, damage to the skin, hair, and nails from the use or cleansers (e.g., skin and hair cleansers containing surfactants), make-up, and shaving and cutting, as well as environmental damage such as from the UV light (e.g., sun damage from the sunlight or non-natural sources such as UV lamps and solar simulators), ozone, exhaust, pollution, chlorine and compounds containing chlorine, and cigarette smoke. Effects of external aggressions on the skin, nails, and skin include, but are not limited to, oxidative and/or nitrosative damage to and modifications on lipids, carbohydrates, peptides, proteins, nucleic acids, and vitamins. Effects of external aggressions also include, but are not limited to, loss of cell viability, loss or alteration of cell functions, and changes in gene and/or protein expression.

As used herein, “safe and effective amount” means an amount of compound or composition (e.g., the legume product) sufficient to induce a positive modification in the condition to be regulated or treated, but low enough to avoid serious side effects. The safe and effective amount of the compound or composition will vary with the particular condition being treated, the age and physical condition of the end user, the severity of the condition being treated/prevented, the duration of the treatment, the nature of other treatments, the specific compound or product/composition employed, the particular cosmetically-acceptable carrier utilized, and like factors.

Legume Product

What is meant by a “legume product” is a substance derived from a legume fruit. A legume is a plant from the family Leguminosae, which has a dehiscent fruit such as a bean, pea, or lentil. Examples of legumes, include but are not limited to, beans such as soybeans, lentil beans, peas, and peanuts.

The legume product may contain the entire legume fruit (e.g., the legume fruit ground into a powder) or only a portion of the legume (e.g., an extract of the legume). The legume product may be in the form of a fluid (e.g., a mixture of the legume fruit and water) or a solid (e.g., legume fruits powders). When in the form of a fluid, the term “legume product” refers to the solid constituents of the fluid derived from the legume.

The compositions of the present invention comprise a safe and effective amount of the legume product (e.g., soy product). In one embodiment, the composition contains from about 0.001% to about 50%, from about 1% to about 30%, of the legume product (e.g., soy product).

Soy Product

What is meant by a “Soy Product” is a substance derived from the soybean. The soy product may contain only a portion of the soybean (e.g., an extract of the soybean such as a lipid reduced soybean powder or filtered soymilk) or may contain the entire soybean (e.g., a ground powder of the legume). The soy product may be in the form of a fluid (e.g., soymilk) or a solid (e.g., a soybean powder or soymilk powder). When in the form of a fluid, the term “soy product” refers to the solid constituents of the fluid that are derived from the soybean.

In one embodiment, the soy product is soybean powder. Soybean powder may be made by grinding dry soybeans, In one embodiment, the soybean powder has a average particle size of less than about 10 micrometers such as less than about 1 micrometer. In one embodiment, the soybean powder has a moisture content of less than about 10% such as less than about 5%. In one embodiment, the soybean powder is lyophilized.

In one embodiment, the soy product is soymilk or soymilk powder. Soymilk is a combination of solids derived from soybeans and water, the mixture of which has some or all of the insoluble constituents filtered off. Soymilk powder is evaporated soymilk, which in one embodiment, is in a lyophilized or spray-dried form. Procedures for manufacturing soymilk include, but are not limited to, the following three procedures. First, soymilk may be made by placing soybeans into water to allow them to absorb the water. The swelled beans are then ground and additional water is then added. The mixture may then filtered to remove any insoluble residue. Second, soymilk may also be prepared from soybean powder. Soybean powder is thoroughly mixed with water (e.g., for at least one hour), which may then be followed by a filtration process to remove insoluble residues. Third, soymilk can also be reconstituted from soymilk powder by adding water. In one embodiment, soymilk comprises from between about 1% to about 50%, by weight (e.g., from about 5% to about 20%, by weight) of solids from the soybean.

Anti-microbial Treatment of Legume Product

As discussed above, the surface of legume fruits often contain high levels of microorganisms. Thus, prior to use by humans, the legume product needs to be treated to reduce or eliminate such microorganisms.

In one embodiment, the legume products of the present invention have a total microbial content of less than about 10,000 colony-forming units (“cfu”) per gram. In a further embodiment, the soy products of the present invention have a microbial content of less than about 1,000 cfu per gram (such as less than about 100 cfu per gram) of the legume product.

In one embodiment, the legume products of the present invention have a total objectionable microbial content of less than 300 cfu per gram such as less than 150 cfu per gram. In a further embodiment, the legume products of the present invention have an undetectable amount of any objectionable microbials for at least one gram (e.g., at least ten grams) of legume product.

In one embodiment, the legume product is exposed to gamma irradiation. In a further embodiment, the legume product is exposed to between about 2 to about 30 kGy of gamma irradiation, such as between about 5 and about 10 kGy of gamma irradiation. Applicants have unexpectedly found that such treatment reduces the microbial content of the legume product, while maintaining its biological activity (e.g., serine protease inhibitory activity). Applicants have also found that treatment of legume products with gamma irradiation maintains the cosmetic elegance of the legume product, such as maintained its natural colors and did not induce significant malodors.

Other anti-microbial processes that also maintain the protease inhibitory activity of the legume product that can be practiced alone or in combination with gamma irradiation, include, but are not limited to, exposure to x-rays, high energy electron or proton beams, ultraviolet radiation, hydrostatic pressure, and addition of chemical agents possessing antimicrobial activity, and combinations thereof. A complete list of methods for microbial content reduction is set forth in “Disinfection, sterilization, and preservation” 4th edition, Seymour S. Block, pp. 887-888 (1991, Lea & Febiger, Malvern, Pa.).

Applicants have found that processes using thermal treatment may result in a substantial loss in protease inhibitory activity and, thus, should be used with caution. For example, applicants have found that heating soymilk to 100° C. for only 10 minutes reduced the trypsin inhibitory activity of the soymilk from 86% (when maintained at 4° C.) to 46%. Applicants have found that heating soymilk can also result in a change of the color or odor of the soybean product.

Topical Compositions

The topical compositions useful in the present invention involve formulations suitable for topical application to skin. In one embodiment, the composition comprises the soy product and a cosmetically-acceptable topical carrier. In one embodiment, the cosmetically-acceptable topical carrier is from about 50% to abut 99.99%, by weight, of the composition (e.g., from about 80% to about 95%, by weight, of the composition.

The compositions may be made into a wide variety of product types that include but are not limited to lotions, creams, gels, sticks, sprays, shaving creams, ointments, cleansing liquid washes and solid bars, shampoos, pastes, powders, mousses, shaving creams, wipes, patches, nail lacquers, wound dressing and adhesive bandages, hydrogels, films and make-up such as foundations, mascaras, and lipsticks. These product types may comprise several types of cosmetically acceptable topical carriers including, but not limited to solutions, emulsions (e.g., microemulsions and nanoemulsions) , gels, solids and liposomes. The following are non-limitative examples of such carriers. Other carriers can be formulated by those of ordinary skill in the art.

The topical compositions useful in the present invention can be formulated as solutions. Solutions typically include an aqueous solvent (e.g., from about 50% to about 99.99% or from about 90% to about 99% of a cosmetically acceptable aqueous solvent).

Topical compositions useful in the subject invention may be formulated as a solution comprising an emollient. Such compositions preferably contain from about 2% to about 50% of an emollient(s). As used herein, “emollients” refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin. A wide variety of suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972) and the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen, pp. 1656-61, 1626, and 1654-55 (The Cosmetic, Toiletry, and Fragrance Assoc., Washington, D.C., 7th Edition, 1997) (hereinafter “ICI Handbook”) contains numerous examples of suitable materials.

A lotion can be made from such a solution. Lotions typically comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s) and from about 50% to about 90% (e.g., from about 60% to about 80%) of water.

Another type of product that may be formulated from a solution is a cream. A cream typically comprises from about 5% to about 50% (e.g., from about 10% to about 20%) of an emollient(s) and from about 45% to about 85% (e.g., from about 50% to about 75%) of water.

Yet another type of product that may be formulated from a solution is an ointment. An ointment may comprise a simple base of animal or vegetable oils or semi-solid hydrocarbons. An ointment may comprise from about 2% to about 10% of an emollient(s) plus from about 0.1% to about 2% of a thickening agent(s). A more complete disclosure of thickening agents or viscosity increasing agents useful herein can be found in Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972) and the ICI Handbook pp. 1693-1697.

The topical compositions useful in the present invention formulated as emulsions. If the carrier is an emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the carrier comprises an emulsifier(s). Emulsifiers may be nonionic, anionic or cationic. Suitable emulsifiers are disclosed in, for example, U.S. Pat. No. 3,755,560, U.S. Pat. No. 4,421,769, McCutcheon's Detergents and Emulsifiers, North American Edition, pp. 317-324 (1986), and the ICI Handbook, pp. 1673-1686.

Lotions and creams can be formulated as emulsions. Typically such lotions comprise from 0.5% to about 5% of an emulsifier(s). Such creams would typically comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s); from about 20% to about 80% (e.g., from 30% to about 70%) of water; and from about 1% to about 10% (e.g., from about 2% to about 5%) of an emulsifier(s).

Single emulsion skin care preparations, such as lotions and creams, of the oil-in-water type and water-in-oil type are well-known in the cosmetic art and are useful in the subject invention. Multiphase emulsion compositions, such as the water-in-oil-in-water type, as disclosed in U.S. Pat. Nos. 4,254,105 and 4,960,764, are also useful in the subject invention. In general, such single or multiphase emulsions contain water, emollients, and emulsifiers as essential ingredients.

The topical compositions of this invention can also be formulated as a gel (e.g., an aqueous gel using a suitable gelling agent(s)). Suitable gelling agents for aqueous gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable gelling agents for oils (such as mineral oil) include, but are not limited to, hydrogenated butylene/ethylene/styrene copolymer and hydrogenated ethylene/propylene/styrene copolymer. Such gels typically comprises between about 0.1% and 5%, by weight, of such gelling agents.

The topical compositions of the present invention can also be formulated into a solid formulation (e.g., a wax-based stick, soap bar composition, powder, or a wipe containing powder).

Liposomal formulations are also useful compositions of the subject invention. Examples of liposomes are unilamellar, multilamellar, and paucilamellar liposomes, which may or may not contain phospholipids. Such compositions can be prepared by first combining hesperetin with a phospholipid, such as dipalmitoylphosphatidyl choline, cholesterol and water according to the method described in Mezei & Gulasekharam, “Liposomes—A Selective Drug Delivery System for the Topical Route of Administration; Gel Dosage Form”, Journal of Pharmaceutics and Pharmacology, Vol. 34 (1982), pp. 473-474, or a modification thereof. Epidermal lipids of suitable composition for forming liposomes may be substituted for the phospholipid. The liposome preparation may then incorporated into one of the above carriers (e.g., a gel or an oil-in-water emulsion) in order to produce the liposomal formulation. Other compositions and pharmaceutical uses of topically applied liposomes are described in Mezei, M., “Liposomes as a Skin Drug Delivery System”, Topics in Pharmaceutical Sciences (D. D. Breimer and P. Speiser, eds.,), Elsevier Science Publishers B.V., New York, N.Y., 1985, pp. 345-358, PCT Patent Application No. WO96/31194 and U.S. Pat. No. 5,260,065.

The topical compositions useful in the subject invention may contain, in addition to the aforementioned components, a wide variety of additional oil-soluble materials and/or water-soluble materials conventionally used in compositions for use on skin, hair, and nails at their art-established levels.

Additional Cosmetically Active Agents

In one embodiment, the topical composition further comprises another cosmetically active agent in addition to the legume product. What is meant by a “cosmetically active agent” is a compound that has a cosmetic or therapeutic effect on the skin, hair, or nails, e.g., lightening agents, darkening agents such as self-tanning agents, anti-acne agents, shine control agents, anti-microbial agents, anti-inflammatory agents, anti-mycotic agents, anti-parasite agents, external analgesics, sunscreens, photoprotectors, antioxidants, keratolytic agents, detergents/surfactants, moisturizers, nutrients, vitamins, energy enhancers, anti-perspiration agents, astringents, deodorants, hair removers, firming agents, anti-callous agents, and agents for hair, nail, and/or skin conditioning.

In one embodiment, the agent is selected from, but not limited to, the group consisting of hydroxy acids, benzoyl peroxide, sulfur resorcinol, ascorbic acid, D-panthenol, hydroquinone, octyl methoxycinnimate, titanium dioxide, octyl salicylate, homosalate, avobenzone, polyphenolics, carotenoids, free radical scavengers, spin traps, retinoids such as retinol and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogens, steroids such as hydrocortisone, 2-dimethylaminoethanol, copper salts such as copper chloride, peptides containing copper such as Cu:Gly-His-Lys, coenzyme Q10, peptides such as those disclosed in PCT Patent Application WO00/15188, lipoic acid, amino acids such a proline and tyrosine, vitamins, lactobionic acid, acetyl-coenzyme A, niacin, riboflavin, thiamin, ribose, electron transporters such as NADH and FADH2, and other botanical extracts such as aloe vera, and derivatives and mixtures thereof. The cosmetically active agent will typically be present in the composition of the invention in an amount of from about 0.001% to about 20% by weight of the composition, e.g., about 0.01% to about 10% such as about 0.1% to about 5%.

Examples of vitamins include, but are not limited to, vitamin A, vitamin Bs such as vitamin B3, vitamin B5, and vitamin B12, vitamin C, vitamin K, and vitamin E and derivatives thereof.

Examples of hydroxy acids include, but are not limited, to glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid. See, e.g., European Patent Application No. 273,202.

Examples of antioxidants include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine), lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide). Oil-soluble antioxidants suitable for use in the compositions of this invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, and ubiquinone. Natural extracts containing antioxidants suitable for use in the compositions of this invention, include, but not limited to, extracts containing flavonoids and isoflavonoids and their derivatives (e.g., genistein and diadzein), extracts containing resveratrol and the like. Examples of such natural extracts include grape seed, green tea, pine bark, and propolis. Other examples of antioxidants may be found on pages 1612-13 of the ICI Handbook.

Other Materials

Various other materials may also be present in the composition useful in the subject invention. These include humectants, proteins and polypeptides, preservatives and an alkaline agent. Examples of such agents are disclosed in the ICI Handbook, pp.1650-1667. The compositions of the present invention may also comprise chelating agents (e.g., EDTA) and preservatives (e.g., parabens). Examples of suitable preservatives and chelating agents are listed in pp. 1626 and 1654-55 of the ICI Handbook. In addition, the topical compositions useful herein can contain conventional cosmetic adjuvants, such as dyes, opacifiers (e.g., titanium dioxide), pigments, and fragrances.

Mineral Water

The legume product (e.g., soymilk) and compositions of the present invention may be prepared using a mineral water. In one embodiment, the mineral water has a mineralization of at least about 200 mg/L (e.g., from about 300 mg/L to about 1000 mg/L). In one embodiment, the mineral water comprises at least about 10 mg/L of calcium and/or at least about 5 mg/L of magnesium.

The composition and formulations containing such compositions of the present invention may be prepared using methodology that is well known by an artisan of ordinary skill.

Applicants have found that soymilk powder prior to any antimicrobial processing such as gamma irradiation has high levels microbial content, ranging from up to 50,000 cfu per gram. Such products were also found to have detectable levels of objectionable microbial content, such as fecal streptococci, at levels up to 20,000 cfu per gram.

Applicants have exposed various amounts (e.g., from about 1 g to about 200 kg) of soymilk powder to gamma irradiation varying from 1 kGy to 16 kGy. The dose or gamma irradiation needed for a reduction a total microbial content to less than about 100 cfu per gram was found to be about 10 kGy. The dose for one log reduction for fecal streptococci is determined to be about 3 kGy and a dose of about 5 kGy was found to consistently reduce this microbial content within a 10 gram sample of soymilk powder to undetectable levels. However, the amount of gamma irradiation used on the legume product will ultimately be determined by the microbial content and size of the soy product to be so treated.

The inhibition of trypsin-induced cleavage of a fluorescent casein peptide was measured using the EnzChek™ protease assay kit, following manufacturer's instructions (EnzChek™ Protease Assay Kits Product Information, Revised Mar. 15, 1999; Molecular Probes, Eugene Oreg.). In summary, various soy preparations were first diluted in 1X digestion buffer (provided in kit) and incubated at different concentrations with 1000 units of trypsin (Sigma, St. Louis, Mo.) dissolved in 1X digestion buffer. A pure serine protease inhibitor (soybean trypsin inhibitor, from Sigma, St. Louis, Mo.) was used as a positive control at 0.1, 0.01%, and 0.001% w/v. Then, 1.0 mg/ml stock solution of BODIPY FL casein was prepared by adding 0.2 mL of deionized water to the vials supplied with this substrate (provided in kit), then made to a final working concentration of 10 microgram/ml in digestion buffer. Following incubation of the trypsin, with or without the test material, with the BODIPY fluorescent casein substrate at room temperature for one hour, fluorescence was measured (excitation 485 nm/emission 530 nm) on a SpectraMax® Gemini microtiter plate reader (Molecular Devices Corporation, Sunnyvale, Calif.) using Softmax® Pro 3.0 software (Molecular Devices Corporation). Each experiment was performed in three replicates and was repeated twice.

This assay was performed on soy products processed seven different ways. Example A was soybeans ground into powder (Sunlight Foods Corporation, Taipei County, Taiwan, R.O.C.). Example B was soybean powder of Example A exposed to about 8-15 kGy of gamma irradiation. Example C was soybean powder in which the oil in the soybean powder was removed by extraction (Soyafluff® 200W from Central Soya Company, Inc., Fort Weyne, Ind.). Example D was soymilk powder made with dehulled soybeans and water that was subsequently filtered and heated and spray dried (Devansoy Farms, Carroll, Iowa) and exposed to between about 7-9 kGy of gamma irradiation. Example E was soymilk powder obtained by mixing soy beans and water, heating the mixture overnight, and adding 1,3-butylene glycol to the mixture (Flavosterone SB from Ichimaru Pharcos Co., Ltd, Gifu Japan). Example F was soymilk powder obtained by mixing soy beans and water, heating the mixture overnight, and subsequently adding ethanol to the mixture (Flavosterone SE from Ichimaru Pharcos Co., Ltd, Gifu Japan). Example G was an extract of soy proteins (Vegeseryl HGP LS 8572 from Laboratories Serobiologiques S.A., Pulnoy, France). These soy products were compared to Soy Trypsin Inhibitor (STI) (Sigma).

The percent inhibition of trypsin cleavage of the substrate by the different soy preparations was calculated using Microsoft Excel™ and is reported in Table 1.

TABLE 1
% Inhibition of
Tested Product Concentration Trypsin
STI 0.01 43.0
STI 0.1 76.1
Example A 0.01 32.8
Example A 0.1 67.1
Example B 0.01 31.5
Example B 0.1 67.2
Example C 0.01 22.7
Example C 0.1 36.2
Example D 0.01 8.92
Example D 0.1 17.4
Example E 0.01 7.83
Example E 0.1 10.8
Example F 0.01 4.87
Example F 0.1 5.99
Example G 0.1 6.85

As shown in Table 1, STI can inhibit trypsin-induced cleavage in a dose response manner. Example A, which is soybean powder, also significantly inhibited trypsin activity. Further gamma irradiation of the soybean powder (i.e., Example B), while reducing the microbial content of the soybean powder, unexpectedly did not significantly impact the trypsin inhibition activity of the soybean powder. The heat and/or extraction processing of Examples C-G, however, did significantly reduce the trypsin inhibitory activity of the soybean powder.

The ability of soy powder to prevent smoke-induced loss of thiols was evaluated in normal human dermal fibroblasts (Clonetics, San Diego, Calif.). Thiols, chiefly glutathione, are part of the endogenous cellular antioxidant defense system. Glutathione serves as a redox buffer, thereby, maintaining the balance between oxidants and antioxidants. Glutathione is also the preferred substrate for several enzymes such as the glutathione peroxidases (decomposing peroxides) and the glutathione-S-transferases (a major group of detoxification enzymes). See, A. Meister, Cancer Res. 54:1969s-1975s (1994).

Cutaneous antioxidants (both enzymatic and non-enzymatic), including glutathione, are depleted after UV or ozone exposure. See, M. J. Connor and L. A. Wheeler, Photochem. Photobiol. 46:239-246 (1987) and R. M. Tyrrell and M. Pidoux, Photochem. Photobiol. 47:405-412 (1988). In cell culture models, low intracellular glutathione (GSH) levels lead to a higher UV radiation sensitivity. Topical application of cysteine derivatives on rat skin has been shown to protect against UV radiation-induced photodamage; this benefit was correlated with an increase in GSH synthesis. See, L. T. van den Broeke and G. M. J. Beijersbergen van Henegouwen, J. Photochem. Photobiol. B Biol. 27:61-65 (1995); K. Hanada, et al., J. Invest. Dermatol. 108:727-730 (1997); and D. P. T. Steenvoorden, et al., Photochem Photobiol. 67:651-656 (1998). Consequently, glucothione is a major endogenous antioxidant, highly responsive against environmental challenges, able to regulate the tone and the wrinkling of skin, as well as treat external aggression.

In this experiment, normal human neonatal dermal fibroblasts seeded in 24-well format Transwell inserts (Corning Costar, Cambridge, Mass.) were incubated with media containing various concentrations of soymilk powder (gamma irradiated at about 5 kGy) for 24 hours prior to exposure with either placebo (mock) or cigarette smoke (1 cigarette, BASIC Full Flavor 100's cigarettes, Philip Morris, Richmond, Va.) for 10 minutes. Prior to smoke exposure, the medium above the inserts containing the soy product was removed, and the cells were washed 3 times with Dulbecco's Phosphate-Buffered Saline (Life Technologies, Gaithersburg, Md.) before being smoke-exposed with only media below the inserts. Immediately after exposure, the cells were incubated for another 24-hour period with the previous medium. The cells were washed again, 5 times with Dulbecco's Phosphate-Buffered Saline, and intracellular thiols were then measured by adding 60 μM monobromobimane (Molecular Probes, Eugene, Oreg., USA) to the cells and incubating at 37° C. for 30 minutes before the fluorescence reading. In the presence of thiols, the monobromobimane becomes fluorescent. This fluorescence was measured using a CytoFluor® Fluorescence Plate Reader (PerSeptive Biosystems, Framingham, Mass., USA) set with the following filter combination: excitation at 360 nm and emission at 460 nm.

The results of this experiment are set-forth in Table 2.

TABLE 2
Thiols (Percent of Thiols
Soymilk Powder contained in No
concentration Smoke Group;
(weight %) Mean ± S.E.M.)
No Smoke 0  100 ± 6.71
Smoke (10 min.) 0 65.38 ± 7.15 
0.5 91.24 ± 14.25
1 95.39 ± 4.52 
2 106.92 ± 17.06 

These results indicate that gamma irradiated soymilk powder surprisingly afforded a protection against smoke-induced loss of thiols (data represent the mean±Standard of the mean of replicates from 3 independent experiments).

It is understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.

Wu, Jeffrey M., Seiberg, Miri, Liu, Jue-Chen, Saliou, Claude, Miller, Jonathan D.

Patent Priority Assignee Title
10543240, Dec 12 2016 JOHNSON & JOHNSON CONSUMER INC Topical composition containing glycerin and yeast extract
11045416, Aug 30 2018 JOHNSON & JOHNSON CONSUMER INC Topical compositions comprising Pichia anomala and retinol
11110051, Aug 30 2018 JOHNSON & JOHNSON CONSUMER INC Topical compositions comprising Pichia anomala and n-acetyl glucosamine
11166997, Jul 27 2018 JOHNSON & JOHNSON SURGICAL VISION, INC Compositions and methods for treating the eye
11357805, Jul 27 2018 JOHNSON & JOHNSON CONSUMER INC Compositions and methods for treating the eye
11878041, Jul 27 2018 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
11878042, Jul 27 2018 JOHNSON & JOHNSON SURGICAL VISION, INC ; JOHNSON & JOHNSON CONSUMER INC Compositions and methods for treating the eye
7829277, Mar 01 2004 The Regents of the University of California Methods for identifying compounds that suppress chemically-induced carcinogenesis
8759613, Oct 26 2009 University of Louisville Research Foundation, Inc Method of producing a lunasin polypeptide in plants
9066906, Nov 11 2009 University of Louisville Research Foundation, Inc Lunasin-containing complex and purification of lunasin from plants
Patent Priority Assignee Title
3097947,
3625976,
3755560,
4007266, May 03 1968 Choay S.A. Pharmaceutical composition containing vitamin B12, process of making the same and method of treatment
4056637, Jun 08 1976 Japan Natural Food Co. Ltd. Process for preparing food products containing a lactic acid bacteria-fermented product of a cereal germ
4151304, Nov 05 1976 CPPD, INC , A CORP OF IL Method and composition for moisturizing the skin
4190671, Mar 17 1977 Biorex Laboratories Limited Chalcone derivatives
4219569, Oct 10 1978 The Upjohn Company Process for treating inflammation
4223018, Feb 09 1979 Bath composition
4254105, Oct 11 1975 LION KABUSHIKI KAISHA LION CORPORATION Multiple emulsion having a form of water/oil/water phase and process for preparation thereof, and multiple emulsion type cosmetics
4272544, Aug 20 1980 ELIZABETH ARDEN COMPANY, A DIVISION OF LEVER BROTHERS COMPANY Skin cell renewal regime
4278570, Aug 20 1980 ELIZABETH ARDEN COMPANY, A DIVISION OF LEVER BROTHERS COMPANY Cosmetic cleanser formulation
4279930, Oct 10 1978 The Upjohn Company Process for treating inflammation
4297348, Apr 11 1980 Rush-Hampton Industries, Inc. Composition and method for the treatment of acne
4331692, Jul 23 1971 Cocoa fruits and products
4333927, Mar 27 1980 Mitsubishi Kasei Corporation Skin preparation
4368187, Aug 03 1981 FD MANAGEMENT, INC Sensitive-skin care regime
4370315, Feb 22 1977 Sederma Post-depilatory composition reducing progressively the growth of body hair
4382960, Aug 03 1981 FD MANAGEMENT, INC Cosmetic cleanser formulation
4386067, Apr 30 1969 Expanscience Cosmetic compositions
4421769, Sep 29 1981 The Procter & Gamble Company Skin conditioning composition
4427670, Mar 27 1980 Mitsubishi Kasei Corporation Skin preparation
4434095, Feb 04 1979 Institute Organicheskogo Sinteza Cyclic analogue of naturally-occurring phagocytosis-stimulant peptide - threonyl-cyclo-[-N.epsilon. -lysyl-prolyl-arginyl]
4437895, Jul 23 1981 SOCIETE ANONYME DITE: L OREAL Mixture of vegetable oils based on jojoba oil and cosmetic compositions comprising the mixture
4439418, Jul 29 1981 Henkel KGaA Topical preparations for the treatment of seborrhea and process for inhibiting sebum production
4462981, Dec 10 1982 CREATIVE PRODUCTS RESOURCE, INC Cosmetic applicator useful for skin moisturizing and deodorizing
4477434, May 29 1982 Medicinal compositions, foods and beverages having therapeutic effects on diseases of circulatory system and digestive system
4486448, Oct 20 1981 SOCIETE ANONYME DITE: L OREAL Copper lanolate and anti-acne compositions containing the same for topical application to the skin
4488564, Dec 19 1980 L'Oreal Oily composition intended for the treatment of keratin substances and the skin
4515778, Mar 12 1981 Preparation for conditioning and grooming the hair
4524067, Oct 29 1979 Osaka Chemical Laboratory Co., Ltd. Soybean saponins, and a method of isolating the same
4537782, Jan 28 1982 SOCIETE ANONYME DITE: L OREAL Emulsifying system based on a fatty acid or a protein condensate, a polyoxyethylenated sterol and a phosphatide, and a cosmetic or pharmaceutical composition containing the same
4550035, Dec 10 1982 CREATIVE PRODUCTS RESOURCE, INC Cosmetic applicator useful for skin moisturizing and deodorizing
4578267, Aug 05 1982 Morton International, Inc Skin conditioning polymer containing alkoxylated nitrogen salts of sulfonic acid
4584190, Nov 17 1983 Kao Corporation Novel chalcone derivatives and ultraviolet absorbers comprising the same
4603146, Aug 28 1981 Methods for retarding the effects of aging of the skin
4604281, Mar 21 1983 Revlon Consumer Products Corporation Cosmetic and skin treatment compositions containing acetylated sterols
4612192, Jul 22 1983 Henkel Kommanditgesellschaft auf Aktien Oil components for cosmetics and pharmaceuticals
4690821, Feb 10 1984 CREATIVE PRODUCTS RESOURCE, INC Towel for skin moisturizing and drying
4707293, Mar 05 1984 Crinos International Detergent composition
4727088, Feb 06 1984 Neutrogena Corporation Retinoid composition having enhanced bioavailability and percutaneous absorption
4760096, Sep 27 1985 Schering Corporation; KEY PHARMACEUTICALS, INC Moisturizing skin preparation
4793991, Jan 31 1986 Hypoallergenic cosmetics, lip balms and lip sticks
4824662, Jun 15 1987 VI-JON, INC Nail polish remover
4834076, Apr 17 1985 Device for treating the external human epithelium, process for its manufacture and process for using such a device
4847267, Mar 17 1986 SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC Skin treatment composition and method
4851214, Sep 07 1988 CRODA UNIQEMA, INC Deodorants containing N-soya-N-ethyl morpholinium ethosulfate
4859458, Sep 15 1981 Rohm and Haas Chemicals LLC Hair conditioning polymers containing alkoxylated nitrogen salts of sulfonic acid
4867964, Dec 16 1986 L'Oreal Cosmetic composition containing hydroxylated chalcone derivatives and its use for protecting the skin and the hair against luminous radiations, new hydroxylated chalcone derivatives employed and process for their preparation
4871530, Mar 19 1986 L'Oreal Aqueous delayed-foaming cosmetic composition for hair and skin treatment
4885169, Jan 09 1984 Crinos Industria Farmacobiologica Spa. Cosmetic composition containing glycoproteins for the skin care
4895839, Jul 10 1987 INDENZA S.p.A. Pharmaceutical and cosmetic compositions containing complexes of flavanolignans with phospholipids
4906457, Sep 06 1988 RYAN, CLARENCE A Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer
4943462, Jan 17 1989 LINDA HART Nail treatment device
4960588, Nov 16 1988 Helene Curtis, Inc. Hair treatment compositions to impart durable hair set retention properties
4960764, Mar 06 1987 Richardson-Vicks Inc. Oil-in-water-in-silicone emulsion compositions
4970216, Mar 17 1986 SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC Skin treatment composition and method
4971825, Dec 21 1984 Kibun Company Limited Process for producing soy bean milk
4978528, Jun 23 1986 BIO SERAE LABORATOIRES S A Process for preventing degradation of an anti-bacterial composition
5002761, May 02 1988 Henkel Kommanditgesellschaft auf Aktien Hair treatment compositions containing natural ingredients
5006337, Apr 16 1987 Pentapharm AG Medicinal compositions based on spent brewers' grains extract, a process for the preparation thereof, and the use of spent brewers' grains extract for the preparation of cosmetic compositions, and a special brewers' grains extract
5032382, Sep 21 1987 L'Oreal Light-stable screening cosmetic composition containing bixin combined with a lipid-soluble UV filter and its use for protecting the human epidermis against ultra-violet radiation
5032400, Nov 02 1989 HIGH ACRE PRODUCTS, INC Shark liver oil and garlic oil topical analgesic
5043323, Jan 14 1987 INDENA S P A Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
5057417, Jun 12 1987 GENENTECH, INC , A CORP OF DELAWARE Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
5077038, Jul 27 1989 VI-JON, INC Nail polish remover
5077040, Apr 30 1990 Helene Curtis, Inc. Hair-treating microemulsion composition and method of preparing and using the same
5104655, Jul 27 1987 Indena S.p.A. Polyunsaturated acids having vasokinetic action and pharmaceutical and cosmetic formulations containing them
5110603, Jan 31 1991 Kao Corporation; ANDREW JERGENS COMPANY, THE Bathing preparation for colloidal material
5116605, May 24 1990 Composition and skin treatment method therewith for mitigating acne and male-pattern baldness
5118671, Feb 26 1987 INDENA, S P A , VIA RIPAMONTI, 99 -- MILAN, ITALY Complexes of aescin, β-sitosterol or cholesterol, and phospholipids and pharmaceutical compositions containing them
5130142, Oct 31 1990 The Practer & Gamble Company Hair growth regulating composition comprising epithelium cell supernatant-derived growth factor
5147859, Feb 26 1987 Indena S.p.A. Complexes of glycerrhetinic acid with phospholipids and pharmaceutical and cosmetic compositions containing them
5166139, Feb 26 1987 Indena, S.p.A. Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them
5171577, Feb 09 1989 L OREAL, Process for the preparation of foams which can be used in the cosmetics and pharmaceutical field and foams obtained by this process
5179091, Jun 22 1990 Adir et Compagnie Chalcones
5188823, Feb 07 1991 Stepan Company Antiperspirant formulations
5192332, Oct 14 1983 L Oreal Cosmetic temporary coloring compositions containing protein derivatives
5194252, Jul 27 1989 VI-JON, INC Moisture retaining aftershave
5217717, Sep 06 1990 Solae, LLC; SOLAE HOLDINGS LLC Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
5229104, Apr 29 1991 MSD CONSUMER CARE, INC Artificial tanning compositions containing positively charged paucilamellar vesicles
5231090, Jul 30 1990 MIAMI, UNIVERSITY OF THE Treatment for hypercholesterolemia
5248495, Apr 16 1992 Procter & Gamble Company, The Post foaming shaving gel composition
5254331, Sep 12 1991 CHANEL, INC Skin cream composition
5260065, Sep 17 1991 NOVAVAX, INC Blended lipid vesicles
5270042, Feb 23 1993 Medicinal salve composition
5276058, Jun 09 1993 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
5306444, Aug 24 1990 Shiseido Company Ltd. Washing composition capable of preventing and ameliorating skin irritation
5310734, Jul 05 1991 PHOSPHOLIPID GMBH Phospholipid composition
5322839, Sep 13 1991 DSM IP ASSETS B V Protein fraction for cosmetic and dermatology care of the skin
5352443, Jun 15 1992 Shiseido Co., Ltd. Permanent waving composition
5362494, Nov 14 1990 L'Oreal Cosmetic, dermo-pharmaceutical or vesicle-containing composition including clycerol-derived compounds
5364886, Feb 03 1988 Nestec S.A. Process for preparing synergic antioxidant mixture
5393519, Mar 27 1992 Helene Curtis, Inc. Shampoo compositions
5397497, Aug 07 1992 Evonik Goldschmidt GmbH Bath additive composition containing polyglycerol fatty acid ester mixture
5407675, Aug 10 1990 Method and composition for use on the scalp and eyebrow region of a subject
5411742, Aug 24 1992 L Oreal Compositions for the treatment of acne containing a derivative of salicylic acid and derivatives of salicylic acid
5427814, Feb 03 1988 Nestec S.A. Process for protecting a fat against oxidation
5428026, May 24 1991 Nestec S.A. Liposoluble antioxidant mixture
5438044, Jun 30 1992 PHOSPHOLIPID GMBH Phospholipid composition
5439672, Jul 01 1980 L'Oreal Cosmetic composition based on an aqueous dispersion of small lipid spheres
5443839, Mar 09 1988 LVMH RECHERCHE Liposomes containing scutellaria extracts
5443840, Feb 18 1992 L'Oreal Cosmetic and/or pharmaceutical composition containing a dispersion of lipid vesicles, process for the preparation of the said dispersion and dispersion of lipid vesicles
5444092, Jul 20 1994 Method and composition for treating psoriasis
5446605, Dec 24 1992 TEAC Corporation Method and apparatus for moving head from one tape track to another against the risk of damaging the tape
5466452, Feb 28 1991 Phytotech Limited Pharmaceutical compositions for the treatment of skin disorders
5498420, Apr 12 1991 MERZ PHARMA GMBH & CO KGAA Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
5503832, Feb 15 1994 Method for extracting the soluble material from oil-bearing beans or seeds
5505946, Apr 01 1994 Solae, LLC; SOLAE HOLDINGS LLC Bowman-birk inhibitor concentrate compositions and methods for the treatment of pre-malignant tissue
5510391, Oct 22 1993 Mayapple Holdings, LLC Method of treating blood vessel disorders of the skin using vitamin K
5523308, Jun 07 1995 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
5539129, Nov 14 1990 L'Oreal Nonionic amphiphilic compounds derived from glycerol, a process for preparing them, and corresponding intermediate compounds
5545399, Oct 26 1993 CHESEBROUGH-POND S USA CO , DIVISION OF CONOPCO, INC Cosmetic composition
5547661, Feb 22 1994 Helene Curtis, Inc. Antiperspirant deodorant compositions
5554647, Oct 12 1989 N V PERRICONE LLC Method and compositions for treatment and/or prevention of skin damage and aging
5565439, Nov 24 1992 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
5565493, Jul 13 1990 Kao Corporation Collagen metabolism ameliorant and its use in the stimulation of hair growth
5567420, Nov 16 1994 SUN PHARMACEUTICALS CORPORATION Lotion which is temporarily colored upon application
5569663, Dec 30 1993 L Oreal Use of a spin trap in a cosmetic or dermatological composition
5571503, Aug 01 1995 CHANEL, INC Anti-pollution cosmetic composition
5578297, Sep 28 1993 L Oreal Cosmetic compositions containing an expoxidized oil as plasticizer
5589181, Feb 27 1992 Franz, Bencsits; Perycut-Chemie AG Insect repellent
5595984, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5597814, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5601833, Dec 30 1993 L Oreal Protective, nutritive and/or firming composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
5603949, Aug 01 1991 LVMH RECHERCHE Use of a tocopherol phosphate or one of its derivatives, for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
5605894, Nov 25 1991 Procter & Gamble Company, The Compositions for regulating skin wrinkles and/or skin atrophy
5607666, Dec 22 1993 L Oreal Cosmetic or dermatological powder, its preparation process and its uses
5607692, Dec 30 1993 L Oreal Depigmenting composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
5614180, Aug 30 1993 Helene Curtis, Inc. Shampoo-conditioner composition
5614215, Dec 30 1993 L Oreal Cosmetic composition for the simultaneous treatment of the surface and deep layers of the skin, its use
5616572, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5618522, Jan 20 1995 Procter & Gamble Company, The Emulsion compositions
5620692, Dec 23 1993 GTC OATS, INC Oat oil compositions with useful cosmetic and dermatological properties
5622690, Apr 05 1990 GTC OATS, INC Seed-derived proteinaceous compositions for reduction of sunburn cell formation
5626868, Feb 18 1992 L'Oreal Cosmetic and/or pharmaceutical composition containing a dispersion of lipid vesicles, process for the preparation of the said dispersion and dispersion of lipid vesicles
5629015, Dec 30 1993 L Oreal Composition for combating ageing acting simultaneously on the surface layers and deep layers of the skin and use thereof
5629301, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5631318, Jul 25 1990 Sunstar Giken Kabushiki Kaisha Reactive hot-melt elastic sealant composition
5635165, Sep 27 1995 Helene Curtis, Inc. Antiperspirant deodorant compositions
5637316, Dec 30 1993 L Oreal Slimming composition for topical treatment, containing two types of liposomes, and use thereof
5639785, Jun 07 1995 GLOBAL PHARMA LTD Methods for the treatment of baldness and gray hair using isoflavonoid derivatives
5641509, Jun 26 1992 Lancaster Group GmbH Preparation for topical use
5643583, May 02 1994 Laboratoires de Biologie Vegetale Yves Rocher Cosmetic or pharmaceutical composition for topical use
5643587, Feb 15 1996 Avon Products, Inc Composition and method for under-eye skin lightening
5643601, Jun 26 1992 Lancaster Group GmbH Phospholipid-and fluorocarbon-containing cosmetic
5650166, Dec 30 1993 L Oreal Moisturizing composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
5652230, Nov 25 1991 Procter & Gamble Company, The Use of salicyclic acid for regulating skin wrinkles and/or skin atrophy
5653988, Jul 09 1994 Beiersdorf Aktiengesellschaft Shower oil
5660853, Jul 24 1991 L'Oreal Process for manufacturing a cosmetics composition for application to hair, composition obtained by this process and process for cosmetic treatment using the said composition
5665367, Sep 27 1996 Chesebrough-Pond's USA Co., Division of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
5670547, Apr 17 1989 CORIA LABORATORIES, LTD Moisturizing vehicle for topical application of vitamin A acid
5674511, Dec 06 1994 The Procter & Gamble Company Shelf stable skin cleansing liquid with gel forming polymer, lipid and crystalline ethylene glycol fatty acid ester
5676935, Sep 28 1993 L'Oreal Cosmetic composition containing an epoxidized oil as plasticizer
5676956, Feb 15 1996 Avon Products, Inc Composition and method for reducing under-eye puffiness
5679374, Dec 30 1993 L Oreal Anti-acne composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
5681571, Oct 08 1993 Duotol AB Immunological tolerance-inducing agent
5681852, Nov 12 1993 TEXTILE RESEARCH INSTITUTE INC Desquamation compositions
5683683, Sep 21 1995 Helene Curtis, Inc. Body wash composition to impart conditioning properties to skin
5686102, Jun 26 1992 Lancaster Group GmbH Pharmacological composition for topical administration
5688763, Jun 12 1987 Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
5691327, Nov 25 1991 Procter & Gamble Company, The Use of salicyclic acid for regulating skin wrinkles and/or skin atrophy
5712356, Nov 26 1993 Novartis AG Cross-linkable copolymers and hydrogels
5723148, Jan 05 1995 Novartis Corp. Topical pharmaceutical compositions
5741496, Sep 21 1993 Laboratoires de Biologie Vegetale Yves Rocher Process for the treatment of skins having dry areas and greasy areas
5753612, Oct 27 1992 Yissum Research Development Company of the Hebrew University of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
5755814, Mar 17 1993 Dermal-epidermal in vitro test system
5762916, Dec 18 1993 COGNIS DEUTSCHLAND GMBH & CO KG Cosmetic and/or pharmaceutical preparations
5766628, Feb 24 1992 MERZ PHARMA GMBH & CO KGAA Bath and shower composition having vesicle-forming properties and method for the production and use thereof
5776917, Nov 25 1991 Procter & Gamble Company, The Compositions for regulating skin wrinkles and/or skin atrophy
5780456, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5780457, Mar 09 1983 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5780458, Nov 25 1991 Procter & Gamble Company, The Use of salicyclic acid for regulating skin wrinkles and/or skin atrophy
5780459, Nov 25 1991 Procter & Gamble Company, The Compositions for regulating skin wrinkles and or skin atrophy
5786345, Nov 25 1991 Procter & Gamble Company, The Compositions for regulating skin wrinkles and/or skin atrophy
5786346, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5789396, Nov 25 1991 Procter & Gamble Company, The Compositions for regulating skin wrinkles and/or skin athropy
5795879, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5801163, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5804216, Feb 23 1995 L Oreal Acidic composition based on lipid vesicles and its use in topical application
5807545, Mar 19 1991 The Procter & Gamble Co. Cosmetic compositions containing hydrophobically modified nonionic polymer and unsaturated quaternary ammonium surfactant
5824702, Jun 07 1996 Mount Sinai School of Medicine of New York University Genistein as a preventive against ultraviolet induced skin photodamage and cancer
5833965, Feb 22 1994 Helene Curtis, Inc. Topically effective antiperspirant compositions
5834013, Jun 08 1994 L Oreal Cosmetic or dermatological composition in the form of an aqueous and stable dispersion of cubic gel particles based on phytanetriol and containing a surface-active agent which has a fatty chain, as dispersing and stabilizing agent
5840717, Nov 25 1991 Procter & Gamble Company, The Use of salysylic acid for regulating skin wrinkles and/or skin atrophy
5843926, Nov 25 1991 Procter & Gamble Company, The Use of salicyclic acid for regulating skin wrinkles and/or skin atrophy
5863546, Mar 02 1997 Cosmetic composition
5869470, Nov 25 1991 Procter & Gamble Company, The Compositions for regulating skin wrinkles and/or skin atrophy
5871743, Oct 31 1996 Topical application of soy molasses
5871823, Jun 19 1996 Huels Aktiengesellschaft Hydrophilic coating of surfaces of polymeric substrates
5880314, Nov 24 1995 Mitsui Chemicals, Inc Hydrochalcone derivatives, cosmetic compositions containing said derivatives and methods of producing the same
5885593, Jul 17 1996 The Andrew Jergens Company Skin care composition including cyclodextrin materials and method for treating skin therewith
5885596, Jul 23 1997 Bristol-Myers Squibb Company Methods and compositions for fine lines and/or wrinkles
5885600, Apr 01 1997 Burlington Bio-Medical & Scientific Corp.; BURLINGTON BIO-MEDICAL & SCIENTIFIC CORP Natural insect repellent formula and method of making same
5885617, Jul 12 1994 CRYOLIFE, INC Moisture barrier film coating composition, method, and coated form
5885948, Feb 15 1995 The Procter & Gamble Company Crystalline hydroxy waxes as oil in water stabilizers for skin cleansing liquid composition
5908618, Dec 27 1996 L Oreal Topical composition containing at least one protein
5912175, Jan 29 1990 BIOPLAST MEDICAL, LLC Process and media for the growth of human cornea and gingiva
5916577, Mar 22 1996 Lancaster Group GmbH Cosmetic with condensates of plant and animal decomposition products
5928654, Apr 17 1996 SOCIETE L OREAL S A Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors
5928658, Dec 05 1997 U.S. Cosmetics Oil-free wax-free solid cosmetic composition
5928889, Feb 13 1998 S.C. Johnson & Son, Inc.; S C JOHNSON & SON, INC Protocol for simulated natural biofilm formation
5936052, Nov 26 1993 Novartis AG Cross-linkable copolymers and hydrogels
5942479, May 27 1995 The Proctor & Gamble Company Aqueous personal cleansing composition with a dispersed oil phase comprising two specifically defined oil components
5945095, Jun 21 1995 L'Oreal Cosmetic composition including a polymeric particle dispersion
5945109, Mar 29 1996 S.W. Patentverwertungs Ges.m.b.H.; S W PATENTVERWERTUNGS GES M B H Cosmetic or cosmetic product for firming and smoothing the skin, in particular in the case of cellulite
5952373, Dec 13 1994 Beiersdorf AG Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
5958387, Mar 14 1994 L'Oreal Aqueous make-up gel containing organopolysiloxane
5961980, Jan 18 1996 The Trustees of the University of Pennsylvania Bowman-birk inhibitor compositions and methods for the treatment of genitourinary diseases
5962015, May 02 1997 KOBO PRODUCTS, INC Stabilized liposomes
5962441, Nov 25 1991 Procter & Gamble Company, The Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
5965153, Mar 24 1998 Stabar Enterprises, Inc. Dietary supplement for preventing or reducing shedding by animals
5972355, Sep 30 1997 E-L Management Corp Stable compositions containing biologically active components
5981450, Sep 16 1994 COGNIS DEUTSCHLAND GMBH & CO KG Mild detergent mixtures
5985338, Sep 13 1996 Abbott Laboratories Plant protein for nutritional products and method of making same
5985809, May 27 1995 The Procter & Gamble Company Aqueous personal cleansing compositions comprising specific nonocclusive liquid polyol fatty acid polyester
5990291, May 29 1998 Archer-Daniels-Midland Company Recovery of isoflavones from soy molasses
6004915, May 27 1995 Procter & Gamble Company, The Cleansing compositions
6013250, Jun 28 1995 L OREAL S A Composition for treating hair against chemical and photo damage
6013255, Apr 18 1994 BASF Aktiengesellschaft Stable water-in-oil emulsions
6017549, Sep 30 1997 E-L Management Corp Non-irritating cosmetic and pharmaceutical compositions
6017893, Aug 30 1996 NATURE S SUNSHINE PRODUCTS, INC Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
6018001, Jan 23 1997 Menicon Co., Ltd. Process for producing contact lens with hydrophilic surface and contact lens obtained thereby
6019962, Nov 07 1995 GALLERIA CO Compositions and methods for improving cosmetic products
6030931, Feb 03 1998 Chesebrough-Pond's USA Co., Division of Conopco, Inc. Foaming cleansing skin product
6033680, Dec 06 1994 The Procter & Gamble Company Shelf stable skin cleansing liquid with gel forming polymer and lipid
6045779, Feb 18 1994 COGNIS DEUTSCHLAND GMBH & CO KG Skin and hair aerosol foam preparations containing an alkyl polyglycoside and vegetable oil
6048520, Sep 24 1992 Helene Curtis, Inc. Clear leave-on hair treatment composition and method
6051602, Mar 16 1998 The Procter & Gamble Company Methods for regulating skin appearance
6054137, Dec 19 1997 SOCIETE L OREAL S A Promoting epidermal renewal with phloroglucinol
6060070, Jun 11 1997 PHYSICIANS PHARMACEUTICALS, INC Isoflavonoids for treatment and prevention of aging skin and wrinkles
6063398, Sep 20 1995 L Oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
6080393, Jul 09 1994 JOHNSON & JOHNSON CONSUMER INC ; JOHNSON & JOHNSON CONSUMER COMPANIES, LLC Skin care composition comprising a retinoid
6093411, Mar 16 1998 The Procter & Gamble Company Compositions for regulating skin appearance
6096327, Nov 05 1998 Alphamed Pharmaceuticals Corp Cosmetic compositions containing human type serine protease inhibitors for revitalizing the skin
6126933, Jun 27 1995 Genetics Institute, LLC Methods of treating inflammatory bowel diseases by administering IL-11
6180662, Dec 13 1994 Beiersdorf AG Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
6183761, Mar 16 1998 The Procter & Gamble Company Compositions for regulating skin appearance
6183762, May 27 1997 SEMBIOSYS GENETICS INC Oil body based personal care products
6261603, May 11 1999 Skin cream
6323219, Apr 02 1998 JOHNSON & JOHNSON CONSUMER INC ; JOHNSON & JOHNSON CONSUMER COMPANIES, LLC Methods for treating immunomediated inflammatory disorders
6399083, Nov 16 1999 Unilever Home & Personal Care USA, division of Conopco, Inc. Cosmetic compositions containing chick pea extract and retinoids
6433025, Apr 13 2000 Cyanotech Corporation Method for retarding and preventing sunburn by UV light
6555143, Feb 28 2001 JOHNSON & JOHNSON CONSUMER INC ; JOHNSON & JOHNSON CONSUMER COMPANIES, LLC Legume products
6558656, Apr 20 2000 Oral and topical compositions and methods related thereto in the treatment of acne
20020065300,
20020160061,
20020192313,
20020197244,
20030064048,
20030064049,
20030224075,
20040009142,
20040062731,
20040063593,
AU724988,
CN1081899,
CN1094279,
CN1146876,
CN1166960,
DE19634206,
DE19818849,
DE4432947,
EP273202,
EP341745,
EP393532,
EP421021,
EP473502,
EP476311,
EP508886,
EP574352,
EP581624,
EP582239,
EP643083,
EP643960,
EP655470,
EP661037,
EP707851,
EP713106,
EP758687,
EP774249,
EP811595,
EP814116,
EP963761,
EP1074240,
EP1077063,
EP1192938,
EP1210946,
EP1236402,
EP1236465,
FR2596986,
FR2641696,
FR2685202,
FR2803747,
FR2811226,
JP10175815,
JP11346695,
JP196106,
JP2000302678,
JP3127713,
JP410226642,
JP4169514,
JP4283518,
JP5015574,
JP5114905,
JP5213729,
JP5246932,
JP5320024,
JP5320061,
JP58225003,
JP58225004,
JP59187756,
JP60061513,
JP6145061,
JP6192085,
JP62036304,
JP6236304,
JP63227515,
JP63318711,
JP6368512,
JP6396120,
JP7010772,
JP7196527,
JP7196529,
JP7304655,
JP7304855,
JP8020597,
JP8040824,
JP8059450,
JP812560,
JP8143442,
JP8333260,
JP899891,
JP9059166,
JP9077638,
JP9176033,
JP925212,
JP925214,
KR928851,
KR928853,
RU2066992,
WO15183,
WO43049,
WO51554,
WO62740,
WO62741,
WO62743,
WO62744,
WO62745,
WO69404,
WO69406,
WO69407,
WO69408,
WO134099,
WO135920,
WO207697,
WO8707838,
WO9104283,
WO9107166,
WO9209639,
WO9209650,
WO9406485,
WO9504609,
WO9509002,
WO9509011,
WO9524885,
WO9609806,
WO9619483,
WO9619491,
WO9624371,
WO9624392,
WO9630035,
WO9630396,
WO9631194,
WO9637497,
WO9640121,
WO9640199,
WO9711033,
WO9718904,
WO9735998,
WO9739733,
WO9801107,
WO9802134,
WO9802138,
WO9805333,
WO9809987,
WO9817246,
WO9833089,
WO9849153,
WO9898503,
WO9900110,
WO9904752,
WO9909065,
WO9915917,
WO9924003,
WO9930729,
WO9936050,
WO9939682,
WO9957178,
//////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Feb 28 2001J&J Consumer Companies, Inc.(assignment on the face of the patent)
Jun 28 2001SALIOU, CLAUDEJohnson & Johnson Consumer Companies, IncASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0120330886 pdf
Jul 02 2001WU, JEFFREY M Johnson & Johnson Consumer Companies, IncASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0120330886 pdf
Jul 05 2001SEIBERG, MIRIJohnson & Johnson Consumer Companies, IncASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0120330886 pdf
Jul 09 2001MILLER, JONATHAN D Johnson & Johnson Consumer Companies, IncASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0120330886 pdf
Jul 10 2001LIU, JUE-CHENJohnson & Johnson Consumer Companies, IncASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0120330886 pdf
Jun 23 2015JOHNSON & JOHNSON CONSUMER COMPANIES, LLCJOHNSON & JOHNSON CONSUMER INC MERGER AND CHANGE OF NAME SEE DOCUMENT FOR DETAILS 0360410605 pdf
Jun 23 2015JOHNSON & JOHNSON CONSUMER INC JOHNSON & JOHNSON CONSUMER INC MERGER AND CHANGE OF NAME SEE DOCUMENT FOR DETAILS 0360410605 pdf
Jun 23 2015Johnson & Johnson Consumer Companies, IncJOHNSON & JOHNSON CONSUMER COMPANIES, LLCMERGER SEE DOCUMENT FOR DETAILS 0360430978 pdf
Jun 23 2015JOHNSON & JOHNSON CONSUMER COMPANIES, LLCJOHNSON & JOHNSON CONSUMER INC CORRECTIVE ASSIGNMENT TO CORRECT THE MERGED ENTITY NEW NAME PREVIOUSLY RECORDED AT REEL: 036041 FRAME: 0605 ASSIGNOR S HEREBY CONFIRMS THE MERGER & CHANGE OF NAME 0361430449 pdf
Date Maintenance Fee Events
Aug 18 2010M1551: Payment of Maintenance Fee, 4th Year, Large Entity.
Aug 20 2014M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Sep 06 2018M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Mar 20 20104 years fee payment window open
Sep 20 20106 months grace period start (w surcharge)
Mar 20 2011patent expiry (for year 4)
Mar 20 20132 years to revive unintentionally abandoned end. (for year 4)
Mar 20 20148 years fee payment window open
Sep 20 20146 months grace period start (w surcharge)
Mar 20 2015patent expiry (for year 8)
Mar 20 20172 years to revive unintentionally abandoned end. (for year 8)
Mar 20 201812 years fee payment window open
Sep 20 20186 months grace period start (w surcharge)
Mar 20 2019patent expiry (for year 12)
Mar 20 20212 years to revive unintentionally abandoned end. (for year 12)